Axogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Axogen and other ETFs, options, and stocks.

About AXGN

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. 

CEO
Michael D. Dale
CEOMichael D. Dale
Employees
452
Employees452
Headquarters
Alachua, Florida
HeadquartersAlachua, Florida
Founded
1977
Founded1977
Employees
452
Employees452

AXGN Key Statistics

Market cap
1.48B
Market cap1.48B
Price-Earnings ratio
-653.06
Price-Earnings ratio-653.06
Dividend yield
Dividend yield
Average volume
1.05M
Average volume1.05M
High today
$33.25
High today$33.25
Low today
$30.41
Low today$30.41
Open price
$32.10
Open price$32.10
Volume
3.22M
Volume3.22M
52 Week high
$34.71
52 Week high$34.71
52 Week low
$9.22
52 Week low$9.22

Stock Snapshot

With a market cap of 1.48B, Axogen(AXGN) trades at $32.00. The stock has a price-to-earnings ratio of -653.06.

On 2026-01-23, Axogen(AXGN) stock traded between a low of $30.41 and a high of $33.25. Shares are currently priced at $32.00, which is +5.2% above the low and -3.8% below the high.

Axogen(AXGN) shares are trading with a volume of 3.22M, against a daily average of 1.05M.

During the past year, Axogen(AXGN) stock moved between $9.22 at its lowest and $34.71 at its peak.

During the past year, Axogen(AXGN) stock moved between $9.22 at its lowest and $34.71 at its peak.

AXGN News

Benzinga 15h
Axogen Prices Upsized $124 Million Stock Offering

Axogen, Inc. (NASDAQ:AXGN) stock is trading lower on Thursday with a session volume of 1.92 million compared to the average volume of 885.013 thousand. Axogen’...

Axogen Prices Upsized $124 Million Stock Offering
TipRanks 1d
AxoGen announces $85M common stock offering

Axogen (AXGN) announced that it intends to offer and sell, subject to market and other conditions, $85M of shares of its common stock in a proposed underwritten...

Simply Wall St 2d
Did Strong 2025 Revenue Guidance Just Shift Axogen's Nerve Repair Investment Narrative?

In January 2026, Axogen, Inc. issued preliminary unaudited guidance indicating expected fourth-quarter 2025 revenue of about US$59.9 million and full-year 2025...

Did Strong 2025 Revenue Guidance Just Shift Axogen's Nerve Repair Investment Narrative?

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

More AXGN News

Simply Wall St 6d
Assessing Axogen Valuation After FDA Approval And Higher 2025 Revenue Guidance

Axogen (AXGN) is back in focus after securing FDA approval and a biologics license for its Avance Nerve Graft, alongside preliminary 2025 guidance that indicate...

Assessing Axogen Valuation After FDA Approval And Higher 2025 Revenue Guidance

People also own

Based on the portfolios of people who own AXGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 companies by market cap and showing a subset from that 100.

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.